Sanofi joins Eli Lilly and Novo Nordisk to cap insulin prices. President Joe Biden still wants Congress to enact limits. MORE ⬇️
Amid pressure from both the public and the Biden administration, a third insulin maker announced it is capping insulin prices. The announcement this week by Sanofi means the three largest insulin producers in the world have instituted price caps in recent weeks.
Sanofi said Lantus 100 Units/mL will have a $35 per month cap on out-of-pocket costs for all patients with commercial insurance. The company said Lantus is its most popular form of insulin. The price cap goes into effect Jan. 1, 2024. “Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years,” said Olivier Bogillot, head of U.S. general medicines with Sanofi.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo NordiskThe French drugmaker is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts.
Lire la suite »
In victory for people with diabetes, Sanofi announces insulin price caps, the last of 3 major insulin makers to do soSanofi, along with Eli Lilly and Novo Nordisk, make up about 90% of the insulin market in the U.S. All three have announced price cuts or out-of-pocket caps in recent weeks.
Lire la suite »
Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Lire la suite »
Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Lire la suite »
Rep. Eli Crane joins freshman House Freedom Caucus members in new podcastThe Fresh Freedom podcast will give an inside view of the representatives' work, according to organizer Rep. Eric Burlison, R-Mo.
Lire la suite »
Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%French drugmaker Sanofi SA said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big diabetes drugmakers facing pressure over high costs.
Lire la suite »